CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Molecular Testing for the Management of Pancreatic Cysts and Solid Pancreaticobiliary Lesions

Policy governs coverage and prior authorization requirements for the PathfinderTG®/PancraGEN® molecular test used to evaluate pancreatic cyst fluid and solid pancreaticobiliary lesions for BCBSRI members, affecting Medicare Advantage and Commercial products.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyMolecular Testing for the Management of Pancreatic Cysts and Solid Pancreaticobiliary Lesions

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJan 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization (required for Medicare Advantage; recommended for Commercial) and report using an unlisted CPT code when no specific code exists.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

35total publications identified

4publications on current version

97% / 91%reported probabilities (Benign / Aggressive)

468/492IMP diagnoses lacking GNAS

Unlisted CPT

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Determination and Criteria

Coverage determination

Coverage stance by product type

Medicare Advantage: PathfinderTG® molecular testing (e.g. PancraGEN®) for evaluation of pancreatic cyst fluid and solid pancreaticobiliary lesions is not covered for Medicare Advantage Plans.

Commercial Products: PathfinderTG® molecular testing (e.g. PancraGEN®) is considered not medically necessary for Commercial Products as the evidence is insufficient to determine the effects of the technology on health outcomes.

Some employer groups that are self-funded may have contract exclusions affecting expanded biomarker testing coverage under the state Biomarker Testing Mandate (R.I.G.L. §27-19-81). For self-funded members, plan-specific benefit booklets determine whether a given genetic or molecular test is covered, not medically necessary, or excluded. Refer to the Coding section of the Genetic Testing Services or Proprietary Laboratory Analyses policies and the member's benefit booklet for group-specific coverage determinations.

The current evidence is insufficient to establish clinical validity or clinical utility for the present version of PancraGEN®. Key limitations include that the algorithm relies on classification by presence or absence of multiple "significant molecular alterations," yet the available studies did not assess all five alterations required to fully validate the current test; several retrospective registry studies omitted GNAS testing for large numbers of cases (for example, 468/492 IMP diagnoses were not tested for GNAS), and other studies simplified or did not address certain alterations or clonality. There are no prospective studies that directly measure the test's impact on management or patient outcomes, and available follow-up durations are insufficient given the long natural history of some cystic lesions. Consequently, PancraGEN® lacks the statistical and outcome evidence necessary to support coverage.

Adjunctive testing when definitive pathologic diagnosis cannot be made due to inadequate specimen or equivocal histologic/cytologic findings

Covered when used adjunctively to inform diagnosis or management if first-line pathology is nondiagnostic

Indication: Test is intended as an adjunctive molecular/topographic genotyping assay when a definitive pathologic diagnosis cannot be made because of an inadequate specimen or equivocal histologic/cytologic findings.

Based on intended use of topographic genotyping tests (PathfinderTG®/PancraGEN®).

Policy conclusion: Despite this intended use, PathfinderTG® molecular testing (e.g. PancraGEN®) for pancreatic cyst fluid and solid pancreaticobiliary lesions is not covered for Medicare Advantage Plans and is considered not medically necessary for Commercial Products due to insufficient evidence of clinical utility.

See Coverage determination for product-specific stance.

Covered Indications

Adjunctive testing when definitive pathologic diagnosis cannot be made due to inadequate specimen or equivocal histologic/cytologic findings

Intended clinical role and policy application

Intended role: Topographic genotyping integrates microscopic anatomic pathology with molecular tissue analysis to microdissect areas of interest and increase tumor cell yield for molecular testing; these assays are intended to be used adjunctively when first-line evaluations are inconclusive.

Coverage application: When requested because a specimen is inadequate or histology/cytology is equivocal, PathfinderTG®/PancraGEN® testing will be evaluated under the policy stance: not covered for Medicare Advantage and not medically necessary for Commercial Products due to insufficient evidence of benefit.

Prior authorization is required for Medicare Advantage and recommended for Commercial Products; use an Unlisted CPT code and obtain prior authorization per policy.

Not Covered

PathfinderTG®/PancraGEN® molecular testing of pancreatic cyst fluid and solid pancreaticobiliary lesions is not covered for Medicare Advantage Plans and is considered not medically necessary for Commercial Products because the evidence does not demonstrate clinical validity or clinical utility. For Medicare Advantage members, prior authorization is required; for Commercial Products prior authorization is recommended. Laboratories must not obtain prior authorization on behalf of ordering physicians, and services provided without required authorization may be denied and billed as the laboratory's financial liability.

Billing and Coding

Unlisted CPT CodesCPT

84999	Unlisted miscellaneous pathology procedure
81479	Unlisted molecular pathology procedure

Prior Authorization, Documentation, and Billing Rules

Prior Authorization

Prior Authorization Required

Prior authorization is required for Medicare Advantage Plans and recommended for Commercial Products. Use the online tool for participating providers to obtain authorization. There is no specific CPT coding for some services; report using unlisted CPT codes (e.g., 84999 or 81479) when appropriate.

Medicare Advantage: prior authorization required
Commercial: prior authorization recommended
Unlisted CPT codes may be used when no specific code exists (see Coding Section)

Prior Authorization

Unlisted Genetic Testing Codes Require Authorization

All unlisted genetic testing CPT codes require prior authorization so the payer can determine what service is being rendered and whether it is covered or medically necessary.

All unlisted genetic testing CPT codes require prior authorization

Clinical Background

Pancreatic cysts, including mucinous lesions such as IPMN and mucinous cystic neoplasm, carry variable risk of progression to malignancy and are typically managed with radiologic surveillance and clinical follow-up. Solid pancreaticobiliary lesions have a broad differential that includes malignancy and benign inflammatory processes. Topographic genotyping methods (PathfinderTG®/PancraGEN®) combine microscopic selection of tissue with molecular analysis to increase tumor cell yield and provide algorithmic risk categories (e.g., Benign, Statistically Indolent, Statistically Higher-Risk, Aggressive) based on molecular alterations, cyst fluid testing, and imaging; however, current evidence does not establish that use of PancraGEN® improves patient outcomes.

Definitions and Test Characteristics

Topographic genotyping — definition and clinical use

DefinitionTopographic genotyping integrates microscopic anatomic pathology with molecular tissue analysis to identify and microdissect areas of interest, increasing tumor cell yield for subsequent molecular testing.

Clinical roleUsed adjunctively when definitive pathologic diagnosis cannot be made because of inadequate specimen or equivocal histologic/cytologic findings to inform surveillance or surgical strategy.

Technique detailUnder microscopic examination, areas of interest are identified and microdissected to enrich tumor-cell content for molecular analysis.

Platform examplePathfinderTG® (Interpace Diagnostics) is a proprietary topographic genotyping platform that permits analysis of tissue specimens of any size, including minute needle biopsies and long‑stored paraffin blocks.

PancraGEN® risk categories